Study design
This study was a non-randomized, open-label and parallel-controlled phase 4 trial (ChiCTR2200057278). 904 eligible participants were randomly assigned to four groups using computer-generated random numbers in SPSS, to receive one dose of Ad5-nCoV via intramuscular injection (Ad5-nCoV-IM, 5×10